We are live on ! Find out more
RAPT

RAPT Therapeutics

Delisted

RAPT was delisted on the 2nd of March, 2026.

84 hedge funds and large institutions have $527M invested in RAPT Therapeutics in 2022 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 31 increasing their positions, 26 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

151% more call options, than puts

Call options by funds: $11.5M | Put options by funds: $4.57M

19% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 26

13% more funds holding in top 10

Funds holding in top 10: 89 (+1)

0.69% more ownership

Funds ownership: 11.85%12.53% (+0.69%)

0% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 10

1% less funds holding

Funds holding: 8584 (-1)

15% less capital invested

Capital invested by funds: $616M → $527M (-$89.5M)

Holders
84
Holders Change
-1
Holders Change %
-1.18%
% of All Funds
1.42%
Holding in Top 10
9
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+12.5%
% of All Funds
0.15%
New
10
Increased
31
Reduced
26
Closed
10
Calls
$11.5M
Puts
$4.57M
Net Calls
+$6.92M
Net Calls Change
+$5.24M
Name Holding Trade Value Shares
Change
Change in
Stake
Charles Schwab
26
Charles Schwab
California
$2.78M +$110K +825 +5%
PIM
27
Ponoi II Management
California
$2.65M
SSA
28
Schonfeld Strategic Advisors
New York
$2.64M +$730K +5,480 +43%
Wellington Management Group
29
Wellington Management Group
Massachusetts
$2.15M -$3.08M -23,092 -61%
N
30
Nuveen
North Carolina
$2M -$599K -4,495 -25%
AIIC
31
AJU IB Investment Company
South Korea
$1.82M
TD Asset Management
32
TD Asset Management
Ontario, Canada
$1.76M -$28.5K -214 -2%
UOC
33
UBS O'Connor
Illinois
$1.44M +$1.31M +9,844 New
Bank of New York Mellon
34
Bank of New York Mellon
New York
$1.31M +$103K +773 +9%
Manulife (Manufacturers Life Insurance)
35
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1.13M +$111K +834 +12%
Swiss National Bank
36
Swiss National Bank
Switzerland
$1.01M +$170K +1,275 +22%
ECM
37
ExodusPoint Capital Management
New York
$960K +$877K +6,578 New
JRP
38
Jasper Ridge Partners
California
$833K
Walleye Capital
39
Walleye Capital
New York
$699K -$461K -3,460 -42%
Citigroup
40
Citigroup
New York
$633K +$334K +2,510 +138%
RhumbLine Advisers
41
RhumbLine Advisers
Massachusetts
$585K +$168K +1,260 +46%
California State Teachers Retirement System (CalSTRS)
42
California State Teachers Retirement System (CalSTRS)
California
$570K +$94.6K +710 +22%
AllianceBernstein
43
AllianceBernstein
Tennessee
$513K
Goldman Sachs
44
Goldman Sachs
New York
$511K -$377K -2,830 -45%
State of Wisconsin Investment Board
45
State of Wisconsin Investment Board
Wisconsin
$396K -$113K -850 -24%
Man Group
46
Man Group
United Kingdom
$374K
New York State Common Retirement Fund
47
New York State Common Retirement Fund
New York
$370K +$86.1K +646 +34%
PI
48
Putnam Investments
Massachusetts
$364K +$153K +1,146 +85%
State Board of Administration of Florida Retirement System
49
State Board of Administration of Florida Retirement System
Florida
$340K +$310K +2,329 New
AA
50
ALPS Advisors
Colorado
$321K -$213K -1,600 -42%

RAPT Hedge Fund Activity: Q2 2022 in Review

84 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in RAPT Therapeutics (RAPT) for Q2 2022, worth a combined $527M — down 15% from $616M a quarter earlier.

Fund positioning in RAPT was balanced in Q2 2022: 10 funds opened new positions, 10 closed out, 31 added to existing stakes and 26 trimmed.

The largest buyer was Column Group, adding an estimated $21.3M. The largest seller was Perceptive Advisors, cutting an estimated $14.8M.

  • 84 institutional investors held RAPT Therapeutics (RAPT) as of Q2 2022, down from 85 in Q1 2022.
  • Funds reported $527M of RAPT Therapeutics stock for Q2 2022, down 15% quarter-over-quarter.
  • 10 funds opened new RAPT Therapeutics positions in Q2 2022 and 10 closed out, a net change of 0 holders.
  • The largest RAPT Therapeutics buyer in Q2 2022 was Column Group, an estimated $21.3M added.
  • The largest RAPT Therapeutics seller in Q2 2022 was Perceptive Advisors, an estimated $14.8M sold.

Based on aggregated 13F filings for Q2 2022.